LP
REGN icon

LMR Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

LMR Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,500
Closed -$4.99M – 1615
2025
Q2 		$4.99M Buy
+9,500
New +$5.3M 0.04% 450
2024
Q2 		– Sell
-1,200
Closed -$1.15M – 1272
2024
Q1 		$1.15M Hold
1,200
– – 0.01% 644
2023
Q4 		$1.05M Hold
1,200
– – 0.01% 578
2023
Q3 		$988K Sell
1,200
-5,900
-83% -$4.64M 0.01% 486
2023
Q2 		$5.1M Buy
+7,100
New +$5.47M 0.06% 248

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

LMR Partners's REGN Position: Q2 2026 in Review

LMR Partners increased its Regeneron Pharmaceuticals (REGN) stake by 15,499% in Q2 2026, buying an estimated $15.1M and bringing the position to 22,306 shares worth $13.9M. The position accounts for 0.05% of the portfolio, ranked #323.

LMR Partners first reported a position in REGN in Q3 2014 and has held it in 33 quarters since. The position peaked at $22.9M in Q2 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • LMR Partners held 22,306 shares of Regeneron Pharmaceuticals worth $13.9M as of Q2 2026.
  • LMR Partners bought 22,163 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $15.1M.
  • Regeneron Pharmaceuticals made up 0.05% of LMR Partners's portfolio in Q2 2026, its #323 holding.
  • LMR Partners first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 33 quarters since.
  • LMR Partners's Regeneron Pharmaceuticals position peaked at $22.9M in Q2 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.